Gaithersburg-based Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) to protect infants via maternal immunization.
Novavax also announced it has been awarded a grant of up to $89 million by the Bill & Melinda Gates Foundation to support development of the RSV F Vaccine Phase 3 clinical trial in pregnant women, planned to initiate during the first quarter of 2016.
{iframe}http://www.choosemontgomerymd.com/features/novavax-announces-positive-top-line-data-from-phase-2-clinical-trial-of-rsv?utm_source=MailerMailer&utm_medium=email&utm_content=Novavax+Announces+Positive+Top-Line+Data+from+Phase+2+Clinical+T&utm_campaign=Novavax+Announces+Positive+Top-Line+Data+from+Phase+2+Clinical+Trial#.VhgBjRNVhHw{/iframe}